Neurocrine Biosciences (NBIX) Capital Expenditures Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 6.52% |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 232.22% |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 34.64% |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 147.53% |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 28.56% |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -15.83% |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | -61.38% |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 89.86% |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | 277.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 147.53% |
| Dec 31, 2025 | 28.34% |
| Sep 30, 2025 | -12.91% |
| Jun 30, 2025 | 12.41% |
| Mar 31, 2025 | 12.08% |
| Dec 31, 2024 | 37.14% |
| Sep 30, 2024 | -13.00% |
| Jun 30, 2024 | 125.29% |
| Mar 31, 2024 | -37.47% |
| Dec 31, 2023 | 95.57% |
| Sep 30, 2023 | -66.53% |
| Jun 30, 2023 | 238.39% |
| Mar 31, 2023 | -22.72% |
| Dec 31, 2022 | 78.03% |
| Sep 30, 2022 | -86.49% |
| Jun 30, 2022 | 4.10% |
| Mar 31, 2022 | 133.11% |
| Dec 31, 2021 | -60.06% |
| Sep 30, 2021 | -0.16% |
| Jun 30, 2021 | -35.64% |